卡罗林斯卡研究所的研究表明，CELLINK的I-DOT液体处理系统可以进行遗传癌症诊断研究 返回
卡罗林斯卡研究所（Karolinska Institute）的最新研究表明，I-DOT具有促进癌症诊断基因研究的能力。瑞典的卡罗林斯卡研究所（Karolinska Institute）处于世界癌症研究的最前沿。
卡罗林斯卡研究所和生命科学实验室已经开发出一种称为CUTseq的新方法，该方法可经济高效地鉴定高度异质性肿瘤，这些肿瘤通常具有很强的侵袭性，需要积极治疗。该方法适用于从多个活检组织甚至从薄薄的组织切片的极小部分（即病理学家通常在显微镜下诊断癌症的样本）中提取的DNA。这项研究最近发表在科学杂志《自然通讯》上。
在癌症研究之外，CUTseq还用作鉴定细胞系和监测通量的方法。传统上，液体处理对交叉污染敏感。这项研究表明，I-DOT在CUTseq工作流程中不易受到交叉污染的影响，这与降低成本，更快的结果和增强的重现性相对应。使用I-DOT，研究人员能够完成整个工作流程，从提取提取的RNA和DNA一直到文库纯化一直到大约8小时。
I-DOT由德国公司Dispendix GmbH开发，该公司于2018年11月被CELLINK收购，以扩大其在制药行业市场的占有率。这项研究的结果为I-DOT在肿瘤学研究中的应用奠定了基础，并可以支持细胞系开发中的其他应用。
Karolinska Institute study shows CELLINK’s I-DOT liquid-handling system can enable genetic cancer diagnostic research
New research from the Karolinska Institute has demonstrated the I-DOT’s capability to facilitate genetic research in cancer diagnostics. The Karolinska Institute in Sweden is at the forefront of cancer research in the world.
Karolinska Institute and Science for Life Laboratory have developed a new method called CUTseq, a cost-effective way to identify highly heterogenous tumors that are often very aggressive and require aggressive treatments. The method works with DNA extracted from multiple biopsies and even from very small portions of thin tissue sections, i.e., the type of sample that pathologists commonly rely on to make a diagnosis of cancer under the microscope. The research has been recently published in the scientific journal Nature Communications.
Outside of cancer research, CUTseq is also used as a method of authenticating cell lines and monitoring throughput. Traditionally, liquid handling is sensitive to cross contamination. This study showed I-DOT was not susceptible to cross contamination during the CUTseq workflow, which corresponds to reduced costs, faster results and enhanced reproducibility. Using the I-DOT, the researchers were able to complete the entire workflow from taking the extracted RNA and DNA all the way through library purification to results in ~8 hours.
I-DOT is developed by Germany-based company Dispendix GmbH, a company CELLINK acquired in November 2018 to increase its presence in the pharmaceutical industry market. The results of this study lay the groundwork for I-DOT’s use in oncological research and can support additional applications in cell line development.
